As of Oct 27
| +0.01 / +0.56%|
The 6 analysts offering 12-month price forecasts for Evoke Pharma Inc have a median target of 5.75, with a high estimate of 19.00 and a low estimate of 0.20. The median estimate represents a +223.03% increase from the last price of 1.78.
The current consensus among 7 polled investment analysts is to Hold stock in Evoke Pharma Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.